Everest Organics Ltd

Everest Organics Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Everest Organics Ltd

₹ 422 0.48%
10 Jun - close price
everestorganicsltd.com BSE: 524790
About

Incorporated in 1993, Everest Organics
Ltd manufactures APIs and Intermediates.[1]

Key Points

Product Profile:
a) APIs:[1]
Company has products for Gastroenterology, Hypercholesterolemia, Benign Prostatic, Anti Convulsant, Hypertrophy, Hyperuricemia
and Gout, Anti Thrombotic, Anti Fungal,
Anti Viral, Anti Emetics, Anti Diabetic,
Insomnia, Skeletal muscle relaxant,
Overactive Bladder, Rhino-Conjunctivitis,
etc.

b) Intermediates:[2]
Febuxostat, Ilaprazole, Imatinib, Oseltamivir Phosphate, Abiraterone Acetate, Rivaroxaban, Itraconazole, Omeprazole, Pantoprazole, Rabeprazole, Esomeprazole, Pemetrexed, Pregabalin, Hydroxy, Chloro compound,
Sulphide, Pyrazine, Gancyclovir, Apixaban, Aprepitant, Bilastine, etc.

c) By Products:[2]
Ammonium Sulphate, Sodium Nitrite, Di
Sodium Orthophosphate, Di Ammonium
Phosphate

Website BSE
  • Market Cap ₹ 410 Cr.
  • Current Price ₹ 422
  • High / Low ₹ 477 / 112
  • Stock P/E
  • Book Value ₹ 72.0
  • Dividend Yield 0.00 %
  • ROCE 1.76 %
  • ROE -2.23 %
  • Face Value ₹ 10.0
Edit ratios

Pros

Cons

  • Stock is trading at 5.86 times its book value
  • Company has low interest coverage ratio.
  • Promoter holding has decreased over last quarter: -13.1%
  • The company has delivered a poor sales growth of -0.94% over past five years.
  • Company has a low return on equity of -0.82% over last 3 years.
  • Company has high debtors of 202 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns
Loading peers table ...

Quarterly Results

Figures in Rs. Crores

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
55.10 43.03 45.97 43.29 50.75 42.67 49.45 52.51 52.62 32.45 44.05 42.05 40.93
53.36 44.67 43.20 45.79 48.47 40.15 46.74 49.71 49.67 36.11 40.62 38.03 37.49
Operating Profit 1.74 -1.64 2.77 -2.50 2.28 2.52 2.71 2.80 2.95 -3.66 3.43 4.02 3.44
OPM % 3.16% -3.81% 6.03% -5.78% 4.49% 5.91% 5.48% 5.33% 5.61% -11.28% 7.79% 9.56% 8.40%
0.45 0.39 0.22 5.65 0.69 0.22 0.24 0.13 0.30 0.33 0.14 0.00 0.22
Interest 1.00 0.69 0.85 0.81 0.95 1.29 1.49 1.45 1.24 1.29 1.35 1.40 1.15
Depreciation 0.77 0.99 1.13 1.10 1.26 1.29 1.32 1.33 1.85 1.47 1.47 1.47 1.56
Profit before tax 0.42 -2.93 1.01 1.24 0.76 0.16 0.14 0.15 0.16 -6.09 0.75 1.15 0.95
Tax % 28.57% -5.80% 6.93% -21.77% 85.53% 75.00% 78.57% 93.33% 62.50% 0.00% 0.00% 0.87% -206.32%
0.29 -2.75 0.94 1.52 0.11 0.04 0.03 0.02 0.06 -6.09 0.75 1.14 2.91
EPS in Rs 0.36 -3.44 1.18 1.90 0.14 0.05 0.04 0.02 0.08 -7.61 0.94 1.42 3.00
Raw PDF

Profit & Loss

Figures in Rs. Crores

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
96 106 99 107 112 156 167 182 200 183 197 159
91 98 94 101 105 138 148 159 194 182 186 152
Operating Profit 5 8 6 6 7 18 19 23 6 1 11 7
OPM % 6% 7% 6% 6% 6% 11% 12% 13% 3% 1% 6% 5%
1 -0 -0 1 1 1 1 1 2 7 1 1
Interest 3 3 3 3 3 3 3 3 3 3 5 5
Depreciation 2 3 3 2 3 3 3 3 4 4 6 6
Profit before tax 1 2 0 2 2 12 14 17 2 0 1 -3
Tax % 21% 20% 18% 24% 28% 39% 23% 21% 34% 311% 77% -60%
1 2 0 1 2 8 11 14 1 -0 0 -1
EPS in Rs 0.54 1.69 2.14 9.39 13.62 17.15 1.42 -0.22 0.18 -1.33
Dividend Payout % 0% 0% 0% 0% 0% 11% 7% 9% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: 4%
5 Years: -1%
3 Years: -7%
TTM: -19%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: -1021%
Stock Price CAGR
10 Years: %
5 Years: 28%
3 Years: 43%
1 Year: 237%
Return on Equity
10 Years: 11%
5 Years: 6%
3 Years: -1%
Last Year: -2%

Balance Sheet

Figures in Rs. Crores

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 9 9 3 8 8 8 8 8 8 8 8 10
Reserves -5 -3 3 8 11 18 26 39 39 38 38 60
26 24 28 19 22 21 18 23 39 51 58 48
35 37 42 51 54 60 68 66 92 105 123 107
Total Liabilities 65 67 76 86 94 107 120 135 178 202 227 224
24 24 27 33 34 38 39 44 49 54 52 51
CWIP 0 0 1 1 1 0 1 0 8 12 21 21
Investments 0 0 0 0 0 0 0 0 0 0 0 0
41 42 47 52 60 68 80 92 121 136 153 152
Total Assets 65 67 76 86 94 107 120 135 178 202 227 224

Cash Flows

Figures in Rs. Crores

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
1 4 7 10 5 9 10 14 14 18 16 -5
-3 -3 -7 -8 -4 -5 -6 -12 -17 -16 -13 -5
2 -2 -0 -2 -1 -3 -3 -2 2 -3 -3 16
Net Cash Flow 0 -0 0 0 -0 1 0 -0 -1 0 0 6

Ratios

Figures in Rs. Crores

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 106 100 117 105 124 95 97 102 125 152 185 202
Inventory Days 46 44 55 73 72 71 102 110 110 139 128 168
Days Payable 184 184 235 260 251 190 211 183 212 282 324 355
Cash Conversion Cycle -32 -40 -63 -83 -55 -24 -12 29 24 9 -11 15
Working Capital Days 8 7 6 -15 7 18 30 55 59 67 60 92
ROCE % 13% 19% 11% 13% 13% 35% 35% 34% 6% 4% 6% 2%

Shareholding Pattern

Numbers in percentages

1 Recently
Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
74.15% 74.15% 74.15% 74.15% 74.15% 74.15% 74.15% 74.15% 74.15% 74.15% 74.15% 61.09%
0.03% 0.03% 0.03% 0.03% 0.03% 0.03% 0.03% 0.03% 0.03% 0.05% 0.05% 0.02%
25.82% 25.82% 25.82% 25.83% 25.83% 25.82% 25.82% 25.83% 25.83% 25.81% 25.80% 38.90%
No. of Shareholders 11,24411,25011,10010,83410,63410,49410,24210,0239,7929,9969,3268,756

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls

  • Jul 2020
    Transcript
    Notes
    PPT